Shawn Aspden, a 20-year veteran of the Canadian capital markets, has joined Bloom Burton & Co. as managing director. Mr. Aspden recently served was vice chairman and head of North American institutional equity sales at GMP Securities.
In the role of managing director, Mr. Aspden will expand Bloom Burton’s ability to serve Canadian institutional investors as they consider the important pharmaceutical, biotechnology and healthcare sectors. He will broaden the awareness and distribution of Bloom Burton’s investment banking and advisory capabilities, award-winning equity research, and events such as the firm’s flagship Bloom Burton Healthcare Investor Conference.
Mr. Aspden also will work to expand the awareness of Bloom Burton Investment Group LP, which currently acts as a consultant to a number of investment funds. In addition, he will contribute to the growth and governance of Bloom Burton’s company incubation affiliate, Bloom Burton Development, which has founded many startups, including Grey Wolf Animal Health, Triumvira Immunologics, Appili Therapeutics and Qing Bile Therapeutics.
“We are thrilled to have been able to recruit Shawn to join Bloom Burton and partner with us in a leadership role that will touch all aspects of the firm’s growing business,” president Brian Bloom, said in a statement.
“We have dramatically expanded our direct access to institutional investors, and for the first time, many will benefit from our products, our research and our deep understanding and commitment to the Canadian healthcare sector,” he added.
